MARKET

BMS

Bemis
BMS
NYSE
Delisted
P/E
P/S
P/B
MARKET CAP
24.08
1.292
4.183
5,221,886,370.25
K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
K36 therapeutics is developing its first-in-class mmset inhibitor ktx-1001 for t(4;14) multiple myeloma. K36's abstract has been accepted for presentation at the 65th american society of hematology annual meeting and exposition. Poster to be presented sunday, december 10, 2023 in san diego.
PR Newswire · 12/04/2023 13:00
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle - Wants To Cut Billions In Costs. Here Are The Stocks Affected
Benzinga · 08/29/2023 13:30
Ventyx: Promising, But Data Will Need To Justify Optimistic Valuation
Seeking Alpha · 08/14/2023 04:03

Webull offers Bemis stock information, including NYSE: BMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMS stock methods without spending real money on the virtual paper trading platform.